Title:
Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View
Indication:
Hematologic
Location:
Texas Oncology-McAllen
Title:
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma View
Indication:
Lymphomas
Location:
Texas Oncology-McAllen
Phase: III
Title:
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin View
Indication:
Epithelial Carcinomas
Location:
Texas Oncology-McAllen
Title:
A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL) - CHRONOS-4 View
Indication:
Non-Hodgkin''s Lymphoma
Location:
Texas Oncology-McAllen
Title:
STAR INCB054828 Urothelial FGF/FGFR View
Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations
Indication:
Bladder Cancer
Location:
Texas Oncology-McAllen
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Bladder Cancer
Location:
Texas Oncology-McAllen
Phase: II
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Non-Interv study Palbo HR+/HER2 AdvBC View
Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Title:
Ph3 Abemaciclib HR+ HER2- (monarchE) View
Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph1 TSR-022 Adv Solid Tumors View
Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)
Indication:
Colon Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
STAR Ph3 BLU-285 vs Regorafenib GIST View
Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Indication:
GI Stromal Tumor (GIST)
Location:
Texas Oncology-McAllen
Phase: III
Title:
informCLL™ Registry View
Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)
Indication:
Leukemia
Location:
Texas Oncology-McAllen
Phase: IV
Title:
Ph3b 1L CLL debulk combo View
Description: A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)
Indication:
Leukemia
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph1 TSR-022 Adv Solid Tumors View
Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
STAR Ph2 Poziotinib EGFR/HER2 NSCLC View
Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: II
Title:
STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View
Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: II
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Ph1/2 Tazemetostat r/r DLBCL & FL View
Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101
Indication:
Lymphomas
Location:
Texas Oncology-McAllen
Phase: I/II
Title:
Ph1 TSR-022 Adv Solid Tumors View
Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)
Indication:
Melanoma
Location:
Texas Oncology-McAllen
Phase: I
Title:
STAR Ph2 Itacitinib +/- Ruxo in MF View
Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Indication:
Myelofibrosis
Location:
Texas Oncology-McAllen
Phase: II
Title:
Ph3Andro+HighRad +/- PelvicRad Prostate View
Description: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Indication:
Prostate Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Ph2 Rucaparib mCRPC (TRITON 2) View
Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052
Indication:
Prostate Cancer
Location:
Texas Oncology-McAllen
Phase: II
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Abirat+pred +/- abemaciclib mCRPC View
Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)
Indication:
Prostate Cancer
Location:
Texas Oncology-McAllen
Phase: II
Title:
STAR Ph2 INCMGA00012 mSCAC View
Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy
Indication:
Rectal Cancer
Location:
Texas Oncology-McAllen
Phase: II
Title:
Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View
Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)
Indication:
Renal Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR INCB054828 Urothelial FGF/FGFR View
Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations
Indication:
Urothelial Cancer
Location:
Texas Oncology-McAllen
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Urothelial Cancer
Location:
Texas Oncology-McAllen
Phase: II